Abstract:OBJECTIVE:To investigate the expression of vitronectin (VN) in placental basal plate and its relationship with the pathogenesis of severe preeclampsia. METHODS:From March 2010 to December 2011, 17 patients with early-onset severe preeclampsia who delivered in the Second Hospital of Jilin University were recruited as the early-onset severe preeclampsia group; and 16 women were recruited as the late-onset severe preeclampsia group. Meanwhile, 15 healthy pregnant women who delivered before 34 weeks were defined as the early control group (termination of pregnancy was carried out because of fetal heart malformations), and 15 healthy pregnant women delivered after 34 weeks were defined as the late control group. Immunohistochemistry and semi-quantitative reverse transcription (RT)-PCR were used to investigate the expression of VN protein and mRNA in the placental infarct center and its surrounding tissue of placental basal plate. The levels of serum prothrombin time (PT), part thromboplastin time (APTT) and fibrinogen (FIb) were detected and the international normalized ratio (INR) was calculated. The correlation of abnormal coagulation markers and VN expression levels in the early-onset severe preeclampsia group and the early control group was studied. RESULTS:(1) VN protein was detected in all placental basal plate of the four groups. It was highly expressed in the necrotic tissue of placental infarct center and weakly expressed in the tissue far from the infarcted area. (2) The mean levels of VN protein expression in placental basal plate of the early-onset severe preeclampsia group, the late-onset severe preeclampsia group, the late control group and the early control group were 0.152 ± 0.019, 0.113 ± 0.023, 0.095 ± 0.014 and 0.055 ± 0.010, respectively. And the differences between the groups were statistically significant (P < 0.01). The VN protein expression in placental infarct center, infarct edge, peri-infarct tissue and tissue far from the infarcted area gradually reduced, and the differences were statistically significant (P < 0.01). Compared with the same areas of each group, the differences were not statistically significant (P > 0.05). (3) VN mRNA were detectable in infarct center, infarct edge, per-infarct tissue and tissue far from the infarcted area of placental basal plate. In the early-onset severe preeclampsia group and the early control group, it was statistically higher in infarct center than in tissue far from the infarcted area (P < 0.05). (4) PT of the early-onset severe preeclampsia group was (9.45 ± 0.63) s, significantly shorter than that of the early control group [(9.88 ± 0.17) s, P < 0.05]. While there was no statistically significant difference in APTT, FIB and INR among the four groups (P > 0.05). (5) In the early-onset severe preeclampsia group, VN expression level and PT were significantly negative correlated (r = -0.612, P < 0.05); while in the early control group there was no correlation (r = 0.489, P > 0.05). CONCLUSION:VN was highly expressed in placental basal plate of the early-onset severe preeclampsia group, which caused the imbalance of coagulation and fibrinolysis system and the pathogenesis of severe preeclampsia.

[Vasohibin and VEGF Protein Levels in Placentae from Pregnancies Complicated by Severe Pre-Eclampsia].

Progress in Soluble Vascular Endothelial Growth Factor Receptor-1 and Preeclampsia

Expression of Placental Vascular Growth Factor in Pregnancy-Induced Hypertension

Effect of Vascular Endothelial Growth Factor on Pre-Eclampsia in Pregnant Rats

Relationship Between Expression of Vimentin, Type IV Collagen and Fibronectin in Human Placenta and Pregnancy Induced Hypertension

[Expression of Vitronectin in Placental Basal Plate and Its Relationship with the Pathogenesis of Severe Preeclampsia].

Expression and clinical implication of endothelial glycoprotein,vascular endothelial growth factor and its receptor 1 in preeclampsia

Serum and Placental Interleukin-18 Are Elevated in Preeclampsia

[The Relativity of Vascular Endothelium Growth Factor Receptor-1 and Preeclampsia].

[VCAM-1 and E-selectin Expression in Extravillous Cytotrophoblasts of Severe Preeclampsia].

The relationship between plasma and placental tissue factor, and tissue factor pathway inhibitors in severe pre-eclampsia patients

Expression of Vascular Endothelial Growth Factor in Human Placental Trophoblasts and Angiogenesis in the Chorionic Villi

Declined placental PLAC1 expression is involved in preeclampsia.

Serum visfatin levels in late pregnancy and pre-eclampsia.

The expressions and significances of VEGF and p53 in placenta of normal pregnancy and pre-eclampsia patients

Expressions of survivin protein and survivin mRNA in placenta with pre-eclampsia

Alterations of maternal serum and placental follistatin-like 3 and myostatin in pre-eclampsia.

Increased Expression Levels of Vitronectin in the Maternal-Fetal Interface of Placenta in Early-Onset Severe Preeclampsia

Increased Expression of Fatty Acid Binding Protein 4 in Preeclamptic Placenta and Its Relevance to Preeclampsia.

Reduced Expression of Follicle Stimulating Hormone Receptor Mrna and Protein in Pregnancies Complicated by Pre-Eclampsia

The expression of CXCL12 and VEGF in preeclampsia